Immunocytochemical studies on the renl fate of circulating advanced glycated products

1995 ◽  
Vol 53 ◽  
pp. 946-947
Author(s):  
A. Gugliucci ◽  
M. Bendayan
Keyword(s):  
Renal Tissue ◽  
Diabetic Glomerulopathy ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Great Reactivity ◽  
Chronic Injection ◽  
Stage Renal Disease ◽  
End Stage ◽  
Classical Picture

A growing body of evidence points to a causal relationship between advanced glycation end products (AGE) accumulation in tissues and the development of chronic diabetic complications. Particularly impressive are data showing a dramatic increase in the levels of circulating AGE peptides in diabetic end stage renal disease that correlates with the severity of the nephropathy. We have recently shown that AGE-BSA probes tagged with colloidal gold display great reactivity towards glomerular structures. In the same way, a recent study has shown that chronic injection of AGEBSA but not BSA produces the classical picture of diabetic glomerulopathy in otherwise euglycemic animals. It is apparent from these and other studies that small metabolic fragments of AGE proteins are implicated in these phenomena. It is certain that the kidneys play an important role in the clearance of circulating AGE products from the bloodstream. However, so far little is known about the fate of AGE proteins and AGE peptides in renal tissue.

Increased advanced glycation end products in atherosclerotic lesions of patients with end-stage renal disease

1999 ◽  
Vol 142 (1) ◽  
pp. 67-77 ◽  
Author(s):  
Noriyuki Sakata ◽  
Yoshinobu Imanaga ◽  
Jing Meng ◽  
Yutaka Tachikawa ◽  
Shigeo Takebayashi ◽  
...  
Keyword(s):  
Renal Disease ◽  
Advanced Glycation End Products ◽  
End Stage Renal Disease ◽  
Advanced Glycation ◽  
Atherosclerotic Lesions ◽  
Glycation End Products ◽  
End Products ◽  
Stage Renal Disease ◽  
End Stage

Abstract P350: Association of Plasma Levels of Soluble Receptor for Advanced Glycation End Products and Risk of Kidney Disease is Explained by Baseline Kidney Function

Circulation ◽  
2014 ◽  
Vol 129 (suppl_1) ◽  
Author(s):  
Casey M Rebholz ◽  
Brad C Astor ◽  
Morgan E Grams ◽  
Marc K Halushka ◽  
Mariana Lazo ◽  
...  
Keyword(s):  
Chronic Kidney Disease ◽  
Kidney Disease ◽  
Renal Disease ◽  
Kidney Failure ◽  
End Stage Renal Disease ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Stage Renal Disease ◽  
End Stage

Introduction: Advanced glycation end products and their cell-bound receptors (RAGE) are thought to mediate the adverse effects of dysglycemia and vascular disease through oxidative stress, inflammation, and endothelial dysfunction. The soluble form of RAGE (sRAGE) is a 48-kDa, positively-charged cleavage product of RAGE. There is limited evidence on the role of sRAGE in the pathogenesis of kidney disease. Methods: We conducted cross-sectional and prospective analyses of a case-cohort study nested within the ARIC Study. Plasma sRAGE was measured at baseline (1990-92) in a cohort random sample (n=1,218) and three case groups of participants with incident chronic kidney disease [estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m 2 and ≥25% eGFR decline; n=151], incident end-stage renal disease [U.S. Renal Data System registry; n=152], and incident kidney failure (eGFR <15 mL/min/1.73 m 2 , U.S. Renal Data System registry, or kidney failure-related hospitalization or death; n=266). Results: Baseline sRAGE levels were inversely related to baseline eGFR (r = -0.13). After adjusting for age, sex, and race, one interquartile range increase in log 10 -transformed sRAGE was associated with development of end-stage renal disease [hazard ratio: 1.97; 95% confidence interval (CI): 1.47, 2.64; p<0.001], kidney failure (hazard ratio: 1.59; 95% CI: 1.27, 2.00; p<0.001), and chronic kidney disease (odds ratio: 1.39; 95% CI: 1.06, 1.83; p=0.02). However, none of these associations were significant after additional adjustment for eGFR (all p>0.10; Figure). Conclusions: High sRAGE levels are associated with decreased kidney function. The association of sRAGE with kidney disease risk may be explained by its partial clearance by the kidney.

Advanced Glycation End Products in End-Stage Renal Disease and Their Removal

Nephron ◽  
2001 ◽  
Vol 87 (4) ◽  
pp. 295-303 ◽  
Author(s):  
Reinhard Schinzel ◽  
Gerald Münch ◽  
August Heidland ◽  
Katharina Sebekova
Keyword(s):  
Renal Disease ◽  
Advanced Glycation End Products ◽  
End Stage Renal Disease ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Stage Renal Disease ◽  
End Stage

ADVANCED GLYCATION END-PRODUCTS, NUTRITION AND AORTIC STIFFNESS IN END-STAGE RENAL DISEASE

2018 ◽  
Vol 36 (Supplement 1) ◽  
pp. e290
Author(s):  
G.Vandal-Gélinas ◽  
R. Larivière ◽  
K. Marquis ◽  
F. Mac-Way ◽  
C. Fortier ◽  
...  
Keyword(s):  
Renal Disease ◽  
Advanced Glycation End Products ◽  
End Stage Renal Disease ◽  
Aortic Stiffness ◽  
Advanced Glycation ◽  
Glycation End Products ◽  
End Products ◽  
Stage Renal Disease ◽  
End Stage
Sign in / Sign up

Export Citation Format

Share Document